Scandinavian Pharma Group ApS
APSBankruptCVR 42650668Islands Brygge 108, 2300 København SRetail sale of cosmetic and toilet articles· NACE 4775Est. 2021 · 5 years old— employees
Loading company…
Overview
Scandinavian Pharma Group ApS is a Danish APS based in København S, operating in the Retail sale of cosmetic and toilet articles sector. Incorporated in 2021, the company reported a gross profit of -DKK 307.7k in its latest annual filing.
Gross profit 2023
-307.7K DKK
+2459% vs 2022
EBITDA margin (of gross profit)
102.7 %
−2527% vs 2022
Net profit 2023
-246.6K DKK
-1942% vs 2022
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
-90.6 %
Very weakAmong the 10% lowest rated companies in the industry
20222023
Liquidity ratioCurrent assets ÷ Short-term debt
0.5×
Very weakAmong the 20% lowest rated companies in the industry
20222023
Return on assets (ROA)Net profit ÷ Total assets × 100
-102.2 %
Very weakAmong the 10% lowest rated companies in the industry
20222023
EBITDA — year on year
DKK thousandsKey figures
Annual report 2023| Gross profit | -307.7K DKK | +2459% |
| EBITDA | -316K DKK | -2527% |
| Net profit | -246.6K DKK | -1942% |
| Total assets | 241.4K DKK | +59% |
| Equity | -218.7K DKK | -883% |
| Employees | — | — |
Company information
Legal name
Scandinavian Pharma Group ApS
CVR number
42650668
Legal form
Anpartsselskab
NACE code
Founded
1 September 2021 · 5 years
Share capital
DKK 40,002
Employees
—
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Islands Brygge 108, 2300 København S
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2023), Scandinavian Pharma Group ApS reported a gross profit of -DKK 307.7k. The figures on this page draw on 2 annual filings covering 2022 to 2023. The bottom line showed a net loss of DKK 246.6k.
At the end of 2023, current assets covered short-term debt 0.5 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2023 | 2022 |
|---|---|---|
| Gross profit | -308 | -12 |
| Staff expenses | -8 | -0 |
| EBITDA | -316 | -12 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -316 | -12 |
| Net financials | -2 | -0 |
| Profit before tax | -318 | -12 |
| Tax | -71 | -0 |
| Net profit | -247 | -12 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2023 | 2022 |
|---|---|---|
| Total assets | 241 | 151 |
| Equity | -219 | 28 |
| Long-term debt | 0 | 0 |
| Short-term debt | 460 | 124 |
| Total debt | 460 | 124 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20222023
Equity ratio
-90.6 %
Very weakAmong the 10% lowest rated companies in the industry
20222023
Return on equity
—
20222023
Net profit margin (of gross profit)
<−999 %
20222023
Asset turnover (of gross profit)
-1.27×
20222023
Debt / equity
—
20222023
Sector performance
17 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Liquidity
Current ratioVery weak
Among the 20% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 10% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Efficiency & development
Equity to contributed capitalVery weak
Among the 10% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (4)
HA Management | Management | 2023 – 2025 |
CR Management | Management | 2023 – 2025 |
NH Chief Executive Officer | Chief Executive Officer | 2023 – 2025 |
TM Liquidator | Liquidator | 2025 – 2025 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2023 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
NA Invest ApS
Scandinavian Pharma Group ApS (this company)Board network connections
Board members of Scandinavian Pharma Group ApS also hold positions in 62 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Munkhøj Haslev | Liquidator | 55 companiesMany roles |
| Camilla Rude Bromark | Management | 3 companies |
| Helle Aakvist Jensen | Management | 2 companies |
| Nick Hielscher Abel | Chief Executive Officer | 2 companies |
Frequently asked questions
What is the CVR number of Scandinavian Pharma Group ApS?
Scandinavian Pharma Group ApS is registered with CVR / Virk under CVR 42650668.
What is the gross profit of Scandinavian Pharma Group ApS?
Scandinavian Pharma Group ApS reported a gross profit of -DKK 307.7k in 2023.
Where is Scandinavian Pharma Group ApS headquartered?
Scandinavian Pharma Group ApS's registered address is Islands Brygge 108, st. th.